Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Talphera Inc TLPH

Healthcare

Talphera, Inc., formerly AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the... see more

Add To Watchlist

Recent & Breaking News (NDAQ:TLPH)

AcelRx Pharmaceuticals Presents Phase 3 Results from ARX-04 Clinical Program at JAB Burn and Wound Care Symposium

PR Newswire February 11, 2016

AcelRx Pharmaceuticals to Present at Two Upcoming Investor Events in February

PR Newswire February 3, 2016

AcelRx Pharmaceuticals Announces Presentation of Phase 3 Sufentanil Sublingual 30 mcg Tablet (ARX-04) Data at the European Congress of Ambulatory Surgery

PR Newswire January 21, 2016

AcelRx Pharmaceuticals Announces Anticipated 2016 Milestones

PR Newswire January 10, 2016

AcelRx Completes Protocol Review with FDA and Plans to Initiate Phase 3 Open-Label Study (IAP312) for Zalviso(TM) in 1Q 2016

PR Newswire January 8, 2016

AcelRx Pharmaceuticals Receives Notice of Eligibility for Centralized Review of ARX-04 from European Medicines Agency

PR Newswire December 23, 2015

AcelRx Pharmaceuticals Conducts Pre-NDA Meeting with U.S. Food and Drug Administration for ARX-04

PR Newswire December 14, 2015

AcelRx Pharmaceuticals to Present at Piper Jaffray 27th Annual Healthcare Conference

PR Newswire November 23, 2015

A Look at Equity Market Momentum - Research on Multi-Fineline Electronix, AcelRx Pharmaceuticals, CAI International and Peregrine Pharmaceuticals

Accesswire November 19, 2015

AcelRx Pharmaceuticals Announces Sublingual Sufentanil Data Presentation at the American Society of Regional Anesthesia and Pain Medicine Meeting

PR Newswire November 19, 2015

AcelRx Pharmaceuticals to Present at Jefferies 2015 Global Healthcare Conference

PR Newswire November 10, 2015

AcelRx Pharmaceuticals to Present at Credit Suisse 24th Annual Healthcare Conference

PR Newswire November 5, 2015

AcelRx Pharmaceuticals Presents Data from Phase 3 Clinical Trials Evaluating the Safety and Efficacy of Zalviso in Obese Surgical Patients

PR Newswire November 4, 2015

Where Opportunity is Found - Research on AcelRx Pharmaceuticals, Tandem Diabetes Care, Brightcove and SciQuest

Accesswire November 2, 2015

AcelRx Pharmaceuticals Provides Business Update and Reports Third Quarter and Nine Months 2015 Financial Results

PR Newswire October 29, 2015

AcelRx Pharmaceuticals to Hold Business Update and Third Quarter Financial Results Conference Call and Webcast on Thursday, Oct 29th, 2015

PR Newswire October 26, 2015

AcelRx Pharmaceuticals Announces Presentation Of Phase 3 Data From ARX-04 Sufentanil Sublingual 30 mcg Program At The American Society Of Anesthesiology Meeting

PR Newswire October 23, 2015

AcelRX Pharmaceuticals Announces Presentation Of Phase 3 Sufentanil Sublingual 30mcg Tablet Data At The European Society Of Emergency Medicine Meeting

PR Newswire October 9, 2015

AcelRx Pharmaceuticals Provides Regulatory Update on Zalviso

PR Newswire October 8, 2015

AcelRx Pharmaceuticals Announces Initiation of Clinical Study with ARX-04 in Emergency Room Patients with Moderate-to-Severe Acute Pain

PR Newswire October 6, 2015